# US 2024/0391883 A1 · Heterocyclic compounds for cancer imaging and treatment and methods for their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0391883 A1
- Document ID: US20240391883A1
- Status: Published application
- Kind: A1
- Application number: 18/791,751
- Filed: 2024-08-01
- Published: 2024-11-28
- Earliest claimed: 2015-01-13
- Assignees: The University of British Columbia; British Columbia Cancer Agency Branch
- Applicants: The University of British Columbia; British Columbia Cancer Agency Branch
- Inventors: Raymond John ANDERSEN; Javier Garcia FERNANDEZ; Kunzhong JIAN; Marianne Dorothy SADAR; Nasrin R. MAWJI; Carmen Adriana BANUELOS
- Web page: https://patentgrep.com/patent/US20240391883A1

## CPC

- C07D 249/04: 1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- A61K 31/4164: 1,3-Diazoles
- A61K 31/4192: 1,2,3-Triazoles
- A61K 31/5375: 1,4-Oxazines, e.g. morpholine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 51/0453: {having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole}
- A61K 51/0459: {having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine}
- A61K 51/0463: {having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines}
- A61K 51/0465: {having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame}
- A61P 35/00: Antineoplastic agents
- C07B 59/002: {Heterocyclic compounds}
- C07D 233/60: with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
- C07D 265/30: not condensed with other rings
- C07D 295/084: with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D 295/088: to an acyclic saturated chain
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, X, n1, n2, and n3 are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.

## Claims

### Claim at position 1

-37. (canceled)

### Claim 38

A compound having the following structure (I):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
X is —O—, —S(O)0-2—, —C(═O)—, —C(OR5)2—, —C(OR5)(OC(═O)R13)—, —C(R8R9)—, —C(═CR8R9)—, —N(R9)—, —N(COR9)—, —CHNR8R9—, —C(═NR9)—, —C(═NOR5)—, —C(═N—NHR5)—;
R1 and R2 are each independently H, hydroxyl, —O-heterocyclyl, or —OC(═O)R13;
R3 is optionally substituted heteroaryl;
R5 is each independently H, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
R8 and R9 are each independently H, halogen, —S(O)0-2R5, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, aryl, aralkyl, C1-C10 acyl, or —NR5R5, or R8 and R9 can join to form a unsubstituted or substituted mono-, bi-, or tri-cyclic carbocycle or heterocycle containing from 3 to 20 carbon atoms;
R11a, R11b, R11c and R11d are each independently H, F, Cl, Br, I, 123I, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, —OR5, —OC(═O)R13, C1-C10 acyl, —S(O)0-2R5, —NO2, —CN, —NH2, —NHR5, or —N(R5)2;
R13 is each independently C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
n1 and n2 are each independently 0, 1, or 2;
n3 is 0, 1, 2, 3, 4, or 5; and
wherein at least one of R11a, R11b, R11c and R11d is Cl, Br, I or 123I.

### Claim 39 (depends on 38)

The compound of claim 38, wherein X is —C(R8R9)—.

### Claim 40 (depends on 39)

The compound of claim 39, wherein R8 and R9 are C1-C10 alkyl.

### Claim 41 (depends on 39)

The compound of claim 39, wherein R8 and R9 are methyl.

### Claim 42 (depends on 38)

The compound of claim 38, wherein R3 is an optionally substituted 5-6 membered heteroaryl, wherein said heteroaryl comprises at least one N atom in the ring.

### Claim 43 (depends on 38)

The compound of claim 38, wherein R3 is selected from a group consisting of pyrrole, furan, thiophene, pyrazole, pyridine, pyridazine, pyrimidine, imidazole, thiazole, isoxazole, oxadiazole, thiadiazole, oxazole, triazole, isothiazole, triazine, and tetrazine.

### Claim 44 (depends on 38)

The compound of claim 38, wherein each R13 is independently methyl, ethyl or propyl.

### Claim 45 (depends on 38)

The compound of claim 38, wherein each R13 is methyl.

### Claim 46 (depends on 38)

The compound of claim 38, wherein n3 is 0, 1, or 2.

### Claim 47 (depends on 38)

The compound of claim 38, wherein the optional substituent is each independently selected from the group consisting of —NRgRh, —NRgC(═O)Rh, —NRgC(═O)NRgRh, —NRgC(═O)ORh, —NRgSO2Rh, —OC(═O)NRgRh, —ORg, —SRg, —SORg, —SO2Rg, —OSO2Rg, —SO2ORg, ═NSO2Rg, —SO2NRgRh, —C(═O)Rg, —C(═O)ORg, —C(═O)NRgRh, —CH2SO2Rg, —CH2SO2NRgRh, amino, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and heteroarylalkyl; and
Rg and Rh are the same or different and independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and heteroarylalkyl.

### Claim 48 (depends on 38)

A pharmaceutical composition, comprising a compound of claim 38 and a pharmaceutically acceptable carrier.

### Claim 49 (depends on 48)

The pharmaceutical composition of claim 48, further comprising an additional therapeutic agent.

### Claim 50 (depends on 49)

The pharmaceutical composition of claim 49, wherein the additional therapeutic agent is for treating prostate cancer, breast cancer, ovarian cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, or age-related macular degeneration.

### Claim 51 (depends on 49)

The pharmaceutical composition of claim 49, wherein the additional therapeutic agent is enzalutamide, Galeterone, ARN-509, abiraterone, bicalutamide, nilutamide, flutamide, cyproterone acetate, docetaxel, Bevacizumab (Avastin), OSU-HDAC42, VITAXIN, sunitumib, ZD-4054, Cabazitaxel (XRP-6258), MDX-010 (Ipilimumab), OGX 427, OGX 011, finasteride, dutasteride, turosteride, bexlosteride, izonsteride, FCE 28260, SKF105,111, ODM-201, or radium 233.

### Claim 52 (depends on 38)

A method for treating a condition or disease selected from the group consisting of prostate cancer, breast cancer, ovarian cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, and age-related macular degeneration, comprising administering to a patient in need thereof a compound of claim 38.

### Claim 53 (depends on 52)

The method of claim 52, wherein the condition or disease is prostate cancer.

### Claim 54 (depends on 53)

The method of claim 53, wherein the prostate cancer is castration resistant prostate cancer or androgen-dependent prostate cancer.
